DND Pharmatech Announces Potential Expansion of GLP-1 Obesity Drug to Brain Diseases
Pubilshed 09 Sep.2024 15:12(KST)
D&Di Pharmatech, a company specializing in the development of glucagon-like peptide (GLP)-1 based new drugs, announced on the 9th that CEO Seulgi Lee has been invited to the ‘2024 Good Brain Conference’ to give a presentation titled ‘Expansion of Indications for GLP-1 Based Drugs: Development of Therapeutics for Degenerative Brain Diseases.’
The 2024 Good Brain Conference, hosted by Asia Economy on the 11th at The Plaza Hotel in Sogong-dong, Jung-gu, Seoul, will focus on ‘Sleep, Brain Health, and Digital Tech,’ introducing digital medical technologies for diagnosing and treating sleep problems and discussing cutting-edge brain science and sleep tech both domestically and internationally.
At the conference, CEO Seulgi Lee of D&Di Pharmatech plans to present on the topic ‘GLP-1, the Panacea for Obesity, Expanding into Brain Diseases,’ discussing the potential for expanding target diseases of GLP-1 based new drugs.
GLP-1 is a type of hormone secreted from the small intestine during food intake, functioning to increase insulin synthesis and secretion, inhibit glucagon secretion, and delay digestive absorption processes. Utilizing these characteristics, GLP-1 was first developed as a treatment for diabetes and is currently expanding its potential applications to various diseases including obesity, metabolic-associated steatohepatitis (MASH), cardiovascular diseases, and degenerative brain diseases. In particular, as the mechanism by which GLP-1 drugs target microglia in the brain to block neuroinflammatory responses?one of the main causes of degenerative brain diseases?has been revealed, active global clinical development is underway in fields such as Parkinson’s disease and Alzheimer’s disease.
CEO Seulgi Lee will also introduce NLY01, a long-acting GLP-1 based therapeutic for degenerative brain diseases developed in-house by the company. In a global Phase 2 clinical trial conducted in 2023 targeting Parkinson’s disease patients, significant therapeutic effects were confirmed in a subgroup of younger Parkinson’s patients under 60 years old. Recently, the Multiple Sclerosis Center at Johns Hopkins University School of Medicine received approval from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial plan targeting multiple sclerosis occurring in young patients aged 20 to 40, seeking to expand indications for NLY01.
CEO Seulgi Lee of D&Di Pharmatech said, “I am pleased to be able to introduce our GLP-1 based degenerative brain disease therapeutic NLY01 through this presentation,” adding, “GLP-1 based new drugs have high potential not only for obesity treatment but also for various indications such as degenerative brain diseases and cardiovascular diseases. Our company will do its best to contribute to patient diagnosis and treatment through continuous research and development.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.